FAKTOR-OPTIONSSCHEIN - MODERNA | Market Closed - Boerse Frankfurt Warrants 03:39:26 2024-06-14 pm EDT | ||
| 2.41 EUR | +6.64% |
|
| Current month | +4.68% | ||
| 1 month | -25.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 2.41 | +6.64% |
| 24-06-13 | 2.26 | +3.67% |
| 24-06-12 | 2.18 | 0.00% |
| 24-06-11 | 2.18 | +1.40% |
| 24-06-10 | 2.15 | +3.86% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 03:39 pm EDT
More quotesStatic data
| Product type | Productos Exóticos |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SF3GXU |
| ISIN | DE000SF3GXU3 |
| Date issued | 2021-08-12 |
| Strike | 456 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.07 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30 € |
|---|---|
| Lowest since issue | 1.74 € |
| Spread | 0.01 € |
| Spread % | 0.41% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- Certificat
